Authors: Schouwink, H Ruevekamp, M Oppelaar, H van Veen, R Baas, P Stewart, FA

Citation: H. Schouwink et al., Photodynamic therapy for malignant mesothelioma: Preclinical studies for optimization of treatment protocols, PHOTOCHEM P, 73(4), 2001, pp. 410-417

Authors: Schouwink, H Rutgers, ET van der Sijp, J Oppelaar, H van Zandwijk, N van Veen, R Burgers, S Stewart, FA Zoetmulder, F Baas, P

Citation: H. Schouwink et al., Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma - Dose finding and toxicity results, CHEST, 120(4), 2001, pp. 1167-1174

Authors: Baas, P van Meerbeeck, J Groen, H Schouwink, H Burgers, S Daamen, S Giaccone, G

Citation: P. Baas et al., Caelyx (TM) in malignant mesothelioma: A phase II EORTC study, ANN ONCOL, 11(6), 2000, pp. 697-700

Authors: Klaase, JM Swaanenburg, JCJM Schouwink, H Sosef, MN Bonfrer, JMG Zoetmulder, FAN Rutgers, EJT Baas, P

Citation: Jm. Klaase et al., Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers, PHOTOCHEM P, 71(3), 2000, pp. 351-354

Authors: Schouwink, H Baas, P Rutgers, ETH Zoetmulder, FAN

Citation: H. Schouwink et al., Malignant pleural mesothelioma, EUR RESP J, 13(3), 1999, pp. 706-706

Authors: Schouwink, H Korse, CM Bonfrer, JMG Hart, AAM Baas, P

Citation: H. Schouwink et al., Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma, LUNG CANC, 25(1), 1999, pp. 25-32